<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68920">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02039440</url>
  </required_header>
  <id_info>
    <org_study_id>311_FU2013</org_study_id>
    <secondary_id>2013-004366-34</secondary_id>
    <nct_id>NCT02039440</nct_id>
  </id_info>
  <brief_title>6-year Antibody Check After Third Vaccination Against Japanese Encephalitis</brief_title>
  <official_title>Neutralizing Antibody Titers 6 Years After the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether there are persisting antibodies against
      Japanese Encephalitis 6 years after the last vaccination with IXIARO(R) and to adapt or
      confirm mathematical models accordingly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Japanese Encephalitis (JE) is a potentially devastating mosquito-borne viral disease. The JE
      virus (JEV), a Flavivirus, is endemic to many regions in Asia, and while JE is primarily a
      pediatric disease in the endemic regions, travelers from non-endemic regions to Asia are
      usually naïve to the virus and may be at risk for contracting JE at any age.

      The present study aims to investigate antibody titers at approximately 6 years after the
      third dose of JE vaccine (JE-VC), in a cohort of participants from an earlier booster dose
      trial, to strengthen the statistical model of the duration of protection after the booster.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) for JEV neutralizing antibodies determined by PRNT</measure>
    <time_frame>1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Rate (SPR) defined as rate of subjects with JEV neutralizing antibody titers ≥1:10 in a PRNT</measure>
    <time_frame>1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Projected mean duration of protection after a booster dose of JE-VC</measure>
    <time_frame>1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Post Other Specified Vaccination Encephalitis</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 blood draw</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>One-time blood draw</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who received a booster dose of JE-VC in study IC51-311

          -  Subjects who are willing to give written informed consent to participate in the trial

        Exclusion Criteria:

          -  Subjects who received a further dose of any Japanese Encephalitis Vaccine since study
             IC51-311

          -  Severe immunosuppression (as result of medical conditions or medication) since study
             IC51-311, such as history of radiation therapy or cytostatic therapy

          -  simultaneous participation in another clinical study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herwig Kollaritsch, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Universität Wien, Institut für Spezifische Prophylaxe und Tropenmedizin 1090 Wien, Kinderspitalgasse 15</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Specific Prophylaxis and Tropical Medicine</name>
      <address>
        <city>Vienna</city>
        <state>Kinderspitalgasse 15</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ines Zwazl</last_name>
      <phone>004314016038276</phone>
      <email>tropenmedizin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Herwig Kollaritsch, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>January 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Herwig Kollaritsch</investigator_full_name>
    <investigator_title>Ao.Univ.-Prof. Dr.med.univ.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Encephalomyelitis, Acute Disseminated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
